Form 8-K - Current report:
SEC Accession No. 0001437749-25-004126
Filing Date
2025-02-18
Accepted
2025-02-18 08:15:10
Documents
17
Period of Report
2025-02-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K gnpx20241220c_8k.htm   iXBRL 8-K 40079
2 EXHIBIT 10.1 ex_759848.htm EX-10.1 154632
3 EXHIBIT 99.1 ex_759849.htm EX-99.1 23525
8 a01.jpg GRAPHIC 7436
  Complete submission text file 0001437749-25-004126.txt   395793

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA gnpx-20250217.xsd EX-101.SCH 3410
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE gnpx-20250217_def.xml EX-101.DEF 11425
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE gnpx-20250217_lab.xml EX-101.LAB 15311
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gnpx-20250217_pre.xml EX-101.PRE 11585
19 EXTRACTED XBRL INSTANCE DOCUMENT gnpx20241220c_8k_htm.xml XML 2824
Mailing Address 1601 TRINITY STREET, BLDG. B SUITE 3.322 AUSTIN TX 78712
Business Address 1601 TRINITY STREET, BLDG. B SUITE 3.322 AUSTIN TX 78712 512-537-7997
Genprex, Inc. (Filer) CIK: 0001595248 (see all company filings)

EIN.: 900772347 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38244 | Film No.: 25632806
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)